Post-Pfizer Deal Setback, Ablynx Finds Data Differentiating Its Nanobody Ozoralizumab From Other Anti-TNFs
This article was originally published in The Pink Sheet Daily
Executive Summary
Ablynx releases Phase II open-label extension clinical data showing its lead nanobody, ozoralizumab, allows individualized dosing in rheumatoid arthritis and doesn't induce neutralizing antibodies that affect efficacy, potentially differentiating it from marketed TNF inhibitors.